Crinetics Pharmaceuticals, Inc. (CRNX) Stock
CRNX Key Statistics
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CEO: R. Scott Struthers. Company website
CRNX — Frequently Asked Questions
What is the CRNX stock price today?
Crinetics Pharmaceuticals, Inc. (CRNX) trades at $84.95, up 0.00% on the day, as of Sep 20, 2026 15:01 UTC.
What is Crinetics Pharmaceuticals, Inc.'s market cap?
Crinetics Pharmaceuticals, Inc. has a market capitalisation of $9.00B, calculated from the live CRNX share price and shares outstanding.
What is the P/E ratio of CRNX?
CRNX has no meaningful price-to-earnings ratio: Crinetics Pharmaceuticals, Inc. lost $5.05 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Crinetics Pharmaceuticals, Inc. make?
Crinetics Pharmaceuticals, Inc. generated revenue of $42.16M over the trailing twelve months, which puts the stock at 213.54 times sales.
What is the 52-week range for CRNX?
CRNX has traded between $32.30 and $85.01 over the past 52 weeks, and the last price is 0.1% below that high.
Is Crinetics Pharmaceuticals, Inc. profitable?
No. Crinetics Pharmaceuticals, Inc. is loss-making, with a net margin of -1,189.88% over the trailing twelve months.
What is the analyst price target for CRNX?
Wall Street analysts rate CRNX Buy, with an average price target of $84.86, 0.1% below the current price.
What sector is Crinetics Pharmaceuticals, Inc. in?
Crinetics Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Crinetics Pharmaceuticals, Inc.?
R. Scott Struthers is the chief executive of Crinetics Pharmaceuticals, Inc., which employs 594 people.
Where can I track CRNX in real time?
QFI Terminal shows CRNX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CRNX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CRNX in Terminal See plans